全文获取类型
收费全文 | 32780篇 |
免费 | 1626篇 |
国内免费 | 157篇 |
专业分类
耳鼻咽喉 | 415篇 |
儿科学 | 573篇 |
妇产科学 | 568篇 |
基础医学 | 4320篇 |
口腔科学 | 1182篇 |
临床医学 | 2570篇 |
内科学 | 7913篇 |
皮肤病学 | 797篇 |
神经病学 | 2408篇 |
特种医学 | 1291篇 |
外科学 | 5418篇 |
综合类 | 211篇 |
一般理论 | 2篇 |
预防医学 | 1005篇 |
眼科学 | 499篇 |
药学 | 2204篇 |
中国医学 | 49篇 |
肿瘤学 | 3138篇 |
出版年
2021年 | 556篇 |
2020年 | 291篇 |
2019年 | 451篇 |
2018年 | 624篇 |
2017年 | 435篇 |
2016年 | 483篇 |
2015年 | 581篇 |
2014年 | 767篇 |
2013年 | 864篇 |
2012年 | 1342篇 |
2011年 | 1449篇 |
2010年 | 811篇 |
2009年 | 752篇 |
2008年 | 1332篇 |
2007年 | 1391篇 |
2006年 | 1416篇 |
2005年 | 1462篇 |
2004年 | 1409篇 |
2003年 | 1341篇 |
2002年 | 1346篇 |
2001年 | 1213篇 |
2000年 | 1387篇 |
1999年 | 1195篇 |
1998年 | 377篇 |
1997年 | 278篇 |
1996年 | 283篇 |
1995年 | 287篇 |
1994年 | 240篇 |
1993年 | 237篇 |
1992年 | 796篇 |
1991年 | 759篇 |
1990年 | 681篇 |
1989年 | 698篇 |
1988年 | 677篇 |
1987年 | 667篇 |
1986年 | 678篇 |
1985年 | 597篇 |
1984年 | 431篇 |
1983年 | 350篇 |
1979年 | 341篇 |
1978年 | 233篇 |
1977年 | 199篇 |
1975年 | 199篇 |
1974年 | 227篇 |
1973年 | 207篇 |
1972年 | 197篇 |
1971年 | 210篇 |
1970年 | 203篇 |
1969年 | 224篇 |
1968年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Takahiro Hosokawa Hiroaki Takahashi Yutaka Tanami Yumiko Sato Mayumi Hosokawa Eiji Oguma 《Journal of ultrasound in medicine》2019,38(2):533-538
Portal venous gas is occasionally encountered in children with intestinal pneumatosis, identified on real‐time ultrasound imaging as hyperechoic foci with quick movement. The origin of the portal venous gas can be identified by following the hyperechoic foci along the branches of the portal vein, providing an estimate of the location of intestinal pneumatosis. This approach may be useful for predicting the patient's prognosis. Our report describes 2 cases of portal venous gas while estimating the area of intestinal pneumatosis, which were evaluated with real‐time ultrasound. 相似文献
5.
Satoshi Ebata Ayumi Yoshizaki Takemichi Fukasawa Shunsuke Miura Takehiro Takahashi Hayakazu Sumida Yoshihide Asano Shinichi Sato 《The Journal of dermatology》2019,46(11):1006-1013
Systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) is the most frequent cause of death for SSc but there is still no sufficient treatment available. Although cyclophosphamide (CYC) therapy is a common treatment which has shown statistical efficacy against SSc‐ILD to date, its effects are temporary and not enough. Rituximab (RTX), the anti‐CD20 monoclonal antibody, has recently shown efficacy in many autoimmune diseases. In SSc‐ILD, RTX is also considered to be one of the novel treatment candidates. However, studies of SSc‐ILD in Japanese treated with RTX have only a few case reports. Therefore, in this study, we retrospectively compared nine patients treated with RTX and 30 patients treated with CYC to investigate the efficacy of RTX treatment for Japanese anti‐topoisomerase I‐positive SSc‐ILD patients. At the 24‐month evaluation, the improvement rates of percent predicted of forced vital capacity and percent predicted of diffusing capacity of the lung carbon monoxide in the RTX‐treated group were significantly higher than those in the CYC‐treated group (20.6 ± 8.8% vs 1.1 ± 3.9%; P < 0.05 and 34.0 ± 6.0% vs ?1.5 ± 2.8%; P < 0.01, respectively). In addition, skin thickness scores also showed a marked improvement from 13.5 points before the start of treatment to 5.8 points after 24 months by RTX therapy (P < 0.05). These results suggest that RTX treatment is more effective for Japanese SSc‐ILD patients than CYC treatment. In the future, it is expected that large‐scale clinical trials will show the usefulness of RTX treatment for SSc‐ILD. 相似文献
6.
Aya Yamamura Md Junayed Nayeem Motohiko Sato 《Journal of pharmacological sciences》2019,139(3):254-257
The carcinogenesis and development of prostate cancer are mediated by enhanced Ca2+ signaling. In the present study, the pharmacological profile of the Ca2+-sensing receptor (CaSR) antagonists (calcilytics) was examined in human prostate cancer PC-3 cells. NPS2143 and Calhex 231 blocked extracellular Ca2+-induced increases in cytosolic [Ca2+]. NPS2143 and Calhex 231 inhibited cell proliferation (IC50 = 7.4 and 10.3 μM, respectively) and migration. The exposure to NPS2143 or Calhex 231 down-regulated CaSR protein expression. These results demonstrated that calcilytics inhibited cell proliferation/migration and down-regulated CaSR expression in human prostate cancer cells, suggesting their potential as novel therapeutic drugs for prostate cancer. 相似文献
7.
Tetsuo Mitsui Naoto Fujita Yuhki Koga Reiji Fukano Tomoo Osumi Asahito Hama Katsuyoshi Koh Harumi Kakuda Masami Inoue Takahiro Fukuda Hiromasa Yabe Junko Takita Akira Shimada Yoshiko Hashii Atsushi Sato Yoshiko Atsuta Yoshinobu Kanda Junji Suzumiya Ryoji Kobayashi 《Pediatric blood & cancer》2020,67(4)
8.
9.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献
10.
Satoshi Ebata Ayumi Yoshizaki Takemichi Fukasawa Asako Yoshizaki-Ogawa Yoshihide Asano Kosuke Kashiwabara Koji Oba Shinichi Sato 《The Journal of dermatology》2022,49(1):179-183
The benefit of rituximab (RTX) for systemic sclerosis-associated interstitial lung disease (SSc-ILD) has been shown in previous clinical trials. However, predictors of RTX efficacy have not been clarified. We investigated whether B-cell responsiveness to RTX is related to therapeutic effect. Ten SSc-ILD patients treated with RTX in an independent clinical trial (Japan Registry of Clinical Trials, jRCTs031180373) were included in this analysis. Peripheral B-cell counts were examined retrospectively before RTX administration (baseline) and at 2, 4, 12, and 24 weeks after the first RTX administration, along with percent-predicted forced vital capacity (%FVC) before and 24 weeks after RTX treatment. Relative to baseline, the percentage of residual peripheral blood B cells at 2 weeks after RTX was negatively correlated with the %FVC improvement at the 24-week assessment (r = ?0.41, p = 0.04). In the subgroup with less than 5% B-cell persistence at week 2, %FVC at the 24-week assessment was significantly improved compared to baseline (p = 0.02). In another subgroup with more than 5% residual B cells, %FVC was not significantly different after 24 weeks compared to baseline (p = 0.41). In conclusion, the removal rate of B cells after 2 weeks of RTX treatment may be a useful surrogate marker of subsequent SSc-ILD improvement. 相似文献